Contingency management for Psychotic Disorders

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Douglas Mental Health University Institute, Montréal, Canada
Psychotic Disorders+11 More
Contingency management - Behavioral
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.

Eligible Conditions

  • Psychotic Disorders
  • Cannabis Use Disorders
  • Cognitive Decline
  • Cannabis Dependence
  • Cannabis Use
  • Memory Disturbances
  • Neuroimaging

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Baseline, Day 28

Baseline, Day 28
Change in behavior during fMRI task
Change in brain morphology: cortical thickness
Change in brain morphology: diffusion
Change in brain morphology: gray matter volume
Change in fMRI brain activity pattern

Trial Safety

Safety Progress

1 of 3

Trial Design

5 Treatment Groups

Psychosis patients with cannabis use (Non-abstinent)
1 of 5
Non-Psychiatric controls with cannabis use (Non-abstinent)
1 of 5
Non-Psychiatric Controls without cannabis use
1 of 5
Non-Psychiatric controls with cannabis use (Abstinent)
1 of 5
Psychosis patients with cannabis use (Abstinent)
1 of 5
Active Control
Experimental Treatment

134 Total Participants · 5 Treatment Groups

Primary Treatment: Contingency management · No Placebo Group · N/A

Non-Psychiatric controls with cannabis use (Abstinent)
Behavioral
Experimental Group · 1 Intervention: Contingency management · Intervention Types: Behavioral
Psychosis patients with cannabis use (Abstinent)
Behavioral
Experimental Group · 1 Intervention: Contingency management · Intervention Types: Behavioral
Psychosis patients with cannabis use (Non-abstinent)NoIntervention Group · 1 Intervention: Psychosis patients with cannabis use (Non-abstinent) · Intervention Types:
Non-Psychiatric controls with cannabis use (Non-abstinent)NoIntervention Group · 1 Intervention: Non-Psychiatric controls with cannabis use (Non-abstinent) · Intervention Types:
Non-Psychiatric Controls without cannabis useNoIntervention Group · 1 Intervention: Non-Psychiatric Controls without cannabis use · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency management
2006
Completed Phase 4
~880

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, day 28
Closest Location: Douglas Mental Health University Institute · Montréal, Canada
Photo of quebec 1Photo of quebec 2Photo of quebec 3
2020First Recorded Clinical Trial
2 TrialsResearching Psychotic Disorders
20 CompletedClinical Trials

Who is running the clinical trial?

Douglas Mental Health University InstituteLead Sponsor
21 Previous Clinical Trials
1,779 Total Patients Enrolled
Rachel Rabin, Ph. D.Principal InvestigatorDouglas Mental Health University Institute

Eligibility Criteria

Age Any Age · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a Full-Scale IQ ≥ 75.
You meet the criteria for a psychotic disorder.\n
You are an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.